Merial, now part of Boehringer Ingelheim, has received approval from the FDA to expand the label claims for NexGard (afoxolaner). The flea and tick control product is now approved to prevent Borrelia burgdorferi infections as a direct result of NexGard killing Ixodes scapularis vector ticks, commonly called black-legged ticks (or deer ticks). The FDA approval is based on two controlled laboratory studies that showed that NexGard effectively prevented the transmission of B. burgdorfei infections after dogs were infested with wild-caught I. scapularis ticks 28 days after treatment with NexGard. In addition to killing black-legged ticks, NexGard also kills lone star ticks, American dog ticks and brown dog ticks, and it prevents flea infestations by killing adult fleas before they lay eggs. It is approved for use in dogs and puppies 8 weeks of age or older and weighing more than 4 pounds.
NexGard (afoxolaner) Chewables is a soft, beef-flavored chew for dogs. According to a study, NexGard is highly palatable, with 90 percent of dogs readily accepting the chew. NexGards novel active ingredient, which was developed specifically for the treatment of fleas and ticks, provides protection that kills fleas before they can lay eggs and continues to kill new fleas all month long. NexGard is available by prescription exclusively through veterinarians. For fastest response, visit NexGardForDogs.com.